Abiopharma

🔍 Badawi Paul (Executive)

Company: Sight Sciences, Inc. (SGHT)

Report Date: 2026-01-02

Detailed Transactions and Holdings:

• Sold 25,356 shares of Common Stock at $7.43 per share (Direct)
  Date: 2026-01-02 | Code: S | equity_swap_involved: false | shares_owned_after: 5,937,146.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Sold 11,870 shares of Common Stock at $7.48 per share (Direct)
  Date: 2026-01-06 | Code: S | equity_swap_involved: false | shares_owned_after: 5,925,276.00 | transaction_form_type: 4 | Footnotes: F1, F3

Footnotes:

• F1: Reflects shares of the Issuer's common stock, par value $0.001 per share, sold to cover the Reporting Person's tax liability in connection with the vesting of restricted stock units.
• F2: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $7.29 to $8.07, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F3: Reflects the weighted average price at which the shares of Common Stock were sold. The shares were sold in multiple transactions at prices ranging from $7.39 to $7.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the Staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.